Quest diagnostics presents late breaker study demonstrating diabetes prescription cost reductions achieved for participants in an employer-sponsored health program at the 82nd american diabetes association scientific sessions

Analysis shows participants who stayed in the program at least 6 months reduced their diabetes drug costs by 18% in 2 oral and 3 poster presentations, quest researchers also provided insights into the association of hdl particles with cardiovascular risk in diabetes and benefits of digital health coaching with food delivery to improve diabetes management in food insecure adults secaucus, n.j. , june 6, 2022 /prnewswire/ -- quest diagnostics (nyse: dgx), the world's leading provider of diagnostic information services, today announced that it presented results of six studies at the 82nd american diabetes association scientific sessions, june 3-7, 2022 in new orleans, la.
DGX Ratings Summary
DGX Quant Ranking